Tag Archives: Drug

Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio

Last October, England’s drug-cost watchdogs dealt Eli Lilly a blow when they decreed that the company’s CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn’t cost-effective. So Lilly dished up a new price break—and now the National Institute for Health and Care Excellence (NICE) is on board. The problem, initially, was that Lilly couldn’t provide evidence that Verzenio… Read More »

Federal judge says HHS Secretary Alex Azar exceeded legal authority in setting 340B drug payment rates

A federal court has sided with the American Hospital Association and others in ruling that the Department of Health and Human Services unlawfully cut payment rates for certain outpatient drugs. HHS Secretary Alex Azar exceeded his legal authority in setting new reimbursement rates in the outpatient prospective payment system rule for 2018, United States District… Read More »